 |
 |
|||||
 |
 |
 |
 |
 |
 |
|
Our History
Funded in 2000 in Grenoble, France, Protein’eXpert has been offering contract research services focusing on the engineering and development of valuable and complex recombinant proteins.
Funded in 2000 in Grenoble, France, Protein’eXpert has been offering contract research services focusing on the engineering and development of valuable and complex recombinant proteins.
Protein’eXpert has then extended its range of services to the biomanufacturing of therapeutic protein products for early clinical trials via its integrated subsidiary PX’Pharma in 2004. PX’Pharma has been providing dedicated contract services for process development & scale-up optimization, preclinical and clinical cGMP production.
In 2007, a new subsidiary named PX’Monoclonals has been created to propose services ranging from• 2000 Creation of Protein’eXpert, CRO devoted to the engineering, development and production of valuable recombinant proteins.
• 2004 Set up of the subsidiary PX’Pharma offering cGMP clinical manufacturing services.
• 2007 Set up of the subsidiary PX’Monoclonals in Lyon dedicated to the development of murine and humanized monoclonal antibodies for research and therapeutic purposes.
• 2008 Signature of a co-commercialization agreement with the company Althea Technologies (San Diego, USA)
• 2008 Protein’eXpert changes name to PX’Therapeutics in order to highlight its focus on integrated biotherapeutics development
• 2004 Set up of the subsidiary PX’Pharma offering cGMP clinical manufacturing services.
• 2007 Set up of the subsidiary PX’Monoclonals in Lyon dedicated to the development of murine and humanized monoclonal antibodies for research and therapeutic purposes.
• 2008 Signature of a co-commercialization agreement with the company Althea Technologies (San Diego, USA)
• 2008 Protein’eXpert changes name to PX’Therapeutics in order to highlight its focus on integrated biotherapeutics development
the generation of high affinity murine monoclonal antibodies to the development of chimeric and humanized antibodies for therapeutic use.
On September 2008, Protein’eXpert becomes PX’Therapeutics. This change of name reflects the company’s strategy to accompany biotech and pharma clients all along the development of their biotherapeutic candidates with a mission to optimize timelines and bring value to their pipeline. The combination of protein expertise and manufacturing capabilities of the PX’Therapeutics group allows ensuring a seamless transfer from the discovery stage up to clinical manufacturing steps for complex biotherapeutic project (therapeutic proteins, recombinant vaccines and monoclonal atibodies).
On September 2008, Protein’eXpert becomes PX’Therapeutics. This change of name reflects the company’s strategy to accompany biotech and pharma clients all along the development of their biotherapeutic candidates with a mission to optimize timelines and bring value to their pipeline. The combination of protein expertise and manufacturing capabilities of the PX’Therapeutics group allows ensuring a seamless transfer from the discovery stage up to clinical manufacturing steps for complex biotherapeutic project (therapeutic proteins, recombinant vaccines and monoclonal atibodies).
Zone Minatec Entreprises - 7 parvis Louis Néel - BP50 F 38040 Grenoble
Phone: +33(0)438 023 650 - Fax: +33(0)438 961 038
Phone: +33(0)438 023 650 - Fax: +33(0)438 961 038